-
1
-
-
85045850427
-
Passive immunotherapy of viral infections: “super-antibodies” enter the fray
-
pmid:29379211
-
Walker LM, Burton DR, Passive immunotherapy of viral infections: “super-antibodies” enter the fray. Nat Rev Immunol. Nature Publishing Group; 2018; doi: 10.1038/nri.2017.148 pmid: 29379211
-
(2018)
Nat Rev Immunol. Nature Publishing Group
-
-
Walker, L.M.1
Burton, D.R.2
-
2
-
-
85045841784
-
Monoclonal Antibodies for Emerging Infectious Diseases—Borrowing from History
-
pmid:29513615
-
Marston HD, Paules CI, Fauci AS, Monoclonal Antibodies for Emerging Infectious Diseases—Borrowing from History. N Engl J Med. 2018; 1–4. doi: 10.1056/NEJMp1802256 pmid: 29513615
-
(2018)
N Engl J Med
, pp. 1-4
-
-
Marston, H.D.1
Paules, C.I.2
Fauci, A.S.3
-
3
-
-
85042287795
-
Antibody therapies for the prevention and treatment of viral infections
-
pmid:29263875
-
Salazar G, Zhang N, Fu T-M, An Z, Antibody therapies for the prevention and treatment of viral infections. NPJ vaccines. Springer US; 2017;2: 19. doi: 10.1038/s41541-017-0019-3 pmid: 29263875
-
(2017)
NPJ vaccines. Springer US
, vol.2
, pp. 19
-
-
Salazar, G.1
Zhang, N.2
Fu, T.-M.3
An, Z.4
-
4
-
-
77953655955
-
Industrialization of mAb production technology: the bioprocessing industry at a crossroads
-
pmid:20065641
-
Kelley B, Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs. 2009;1: 443–52. doi: 10.4161/mabs.1.5.9448 pmid: 20065641
-
(2009)
MAbs
, vol.1
, pp. 443-452
-
-
Kelley, B.1
-
5
-
-
85033479478
-
Evolving trends in mAb production processes
-
pmid:29313024
-
Shukla AA, Wolfe LS, Mostafa SS, Norman C, Evolving trends in mAb production processes. Bioeng Transl Med. 2017;2: 58–69. doi: 10.1002/btm2.10061 pmid: 29313024
-
(2017)
Bioeng Transl Med
, vol.2
, pp. 58-69
-
-
Shukla, A.A.1
Wolfe, L.S.2
Mostafa, S.S.3
Norman, C.4
-
6
-
-
84954445565
-
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
-
pmid:26702094
-
Lynch RM, Boritz E, Coates EE, Dezure A, Madden P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7: 319ra206—319ra206. doi: 10.1126/scitranslmed.aad5752 pmid: 26702094
-
(2015)
Sci Transl Med
, vol.7
, pp. 319ra206
-
-
Lynch, R.M.1
Boritz, E.2
Coates, E.E.3
Dezure, A.4
Madden, P.5
Costner, P.6
-
7
-
-
84946480939
-
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
-
pmid:26332605
-
Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182: 289–301. doi: 10.1111/cei.12692 pmid: 26332605
-
(2015)
Clin Exp Immunol
, vol.182
, pp. 289-301
-
-
Ledgerwood, J.E.1
Coates, E.E.2
Yamshchikov, G.3
Saunders, J.G.4
Holman, L.5
Enama, M.E.6
-
8
-
-
84992559547
-
Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications
-
pmid:27622299
-
Sparrow E, Friede M, Sheikh M, Torvaldsen S, Newall AT, Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine. The Authors; 2016;34: 5442–5448. doi: 10.1016/j.vaccine.2016.08.057 pmid: 27622299
-
(2016)
Vaccine. The Authors
, vol.34
, pp. 5442-5448
-
-
Sparrow, E.1
Friede, M.2
Sheikh, M.3
Torvaldsen, S.4
Newall, A.T.5
-
9
-
-
85041611031
-
Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
-
pmid:29721387
-
Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH, Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. Taylor & Francis; 2018; e1424674. doi: 10.1080/2162402X.2018.1424674 pmid: 29721387
-
(2018)
Oncoimmunology. Taylor & Francis
, pp. e1424674
-
-
Kverneland, A.H.1
Enevold, C.2
Donia, M.3
Bastholt, L.4
Svane, I.M.5
Nielsen, C.H.6
-
10
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease
-
pmid:12584368
-
Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348: 601–8. doi: 10.1056/NEJMoa020888 pmid: 12584368
-
(2003)
N Engl J Med
, vol.348
, pp. 601-608
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
Van Assche, G.4
D’Haens, G.5
Carbonez, A.6
-
11
-
-
79960935860
-
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
-
pmid:21427177
-
Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50: 1445–52. doi: 10.1093/rheumatology/ker124 pmid: 21427177
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 1445-1452
-
-
Pascual-Salcedo, D.1
Plasencia, C.2
Ramiro, S.3
Nuño, L.4
Bonilla, G.5
Nagore, D.6
-
12
-
-
33644820684
-
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
-
pmid:16474400
-
Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12: 342–7. doi: 10.1038/nm1358 pmid: 16474400
-
(2006)
Nat Med
, vol.12
, pp. 342-347
-
-
Manno, C.S.1
Pierce, G.F.2
Arruda, V.R.3
Glader, B.4
Ragni, M.5
Rasko, J.J.6
-
13
-
-
84855161388
-
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B
-
pmid:22149959
-
Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365: 2357–65. doi: 10.1056/NEJMoa1108046 pmid: 22149959
-
(2011)
N Engl J Med
, vol.365
, pp. 2357-2365
-
-
Nathwani, A.C.1
Tuddenham, E.G.D.2
Rangarajan, S.3
Rosales, C.4
McIntosh, J.5
Linch, D.C.6
-
14
-
-
85038006730
-
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
-
pmid:29211678
-
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017;377: 2215–2227. doi: 10.1056/NEJMoa1708538 pmid: 29211678
-
(2017)
N Engl J Med
, vol.377
, pp. 2215-2227
-
-
George, L.A.1
Sullivan, S.K.2
Giermasz, A.3
Rasko, J.E.J.4
Samelson-Jones, B.J.5
Ducore, J.6
-
15
-
-
84875962928
-
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL S447X) gene therapy for lipoprotein lipase deficiency: An open-label trial
-
pmid:22717743
-
Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL S447X) gene therapy for lipoprotein lipase deficiency: An open-label trial. Gene Ther. 2013;20: 361–369. doi: 10.1038/gt.2012.43 pmid: 22717743
-
(2013)
Gene Ther
, vol.20
, pp. 361-369
-
-
Gaudet, D.1
Méthot, J.2
Déry, S.3
Brisson, D.4
Essiembre, C.5
Tremblay, G.6
-
16
-
-
84936935341
-
Engineering humoral immunity as prophylaxis or therapy
-
pmid:26183209
-
Deal CE, Balazs AB, Engineering humoral immunity as prophylaxis or therapy. Curr Opin Immunol. Elsevier Ltd; 2015;35: 113–122. doi: 10.1016/j.coi.2015.06.014 pmid: 26183209
-
(2015)
Curr Opin Immunol. Elsevier Ltd
, vol.35
, pp. 113-122
-
-
Deal, C.E.1
Balazs, A.B.2
-
17
-
-
84871195605
-
Antibody gene transfer for HIV immunoprophylaxis
-
pmid:23238748
-
Balazs AB, West AP, Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol. Nature Publishing Group; 2013;14: 1–5. doi: 10.1038/ni.2480 pmid: 23238748
-
(2013)
Nat Immunol. Nature Publishing Group
, vol.14
, pp. 1-5
-
-
Balazs, A.B.1
West, A.P.2
-
18
-
-
85010868233
-
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention
-
pmid:28133808
-
Brady JM, Baltimore D, Balazs AB, Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev. 2017;275: 324–333. doi: 10.1111/imr.12478 pmid: 28133808
-
(2017)
Immunol Rev
, vol.275
, pp. 324-333
-
-
Brady, J.M.1
Baltimore, D.2
Balazs, A.B.3
-
19
-
-
84928552521
-
Vectored antibody gene delivery for the prevention or treatment of HIV infection
-
Deal CE, Balazs AB, Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr Opin HIV AIDS. 2015;10: 1–8
-
(2015)
Curr Opin HIV AIDS
, vol.10
, pp. 1-8
-
-
Deal, C.E.1
Balazs, A.B.2
-
20
-
-
84893123319
-
Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera)
-
pmid:24308784
-
Salmon F, Grosios K, Petry H, Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera). Expert Rev Clin Pharmacol. 2014;7: 53–65. doi: 10.1586/17512433.2014.852065 pmid: 24308784
-
(2014)
Expert Rev Clin Pharmacol
, vol.7
, pp. 53-65
-
-
Salmon, F.1
Grosios, K.2
Petry, H.3
-
21
-
-
84875962928
-
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
-
pmid:22717743
-
Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. Macmillan Publishers Limited; 2013;20: 361–9. doi: 10.1038/gt.2012.43 pmid: 22717743
-
(2013)
Gene Ther. Macmillan Publishers Limited
, vol.20
, pp. 361-369
-
-
Gaudet, D.1
Méthot, J.2
Déry, S.3
Brisson, D.4
Essiembre, C.5
Tremblay, G.6
-
22
-
-
85039954002
-
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
-
pmid:29224506, NEJMoa1708483
-
Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5–Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med. 2017; NEJMoa1708483. doi: 10.1056/NEJMoa1708483 pmid: 29224506
-
(2017)
N Engl J Med
-
-
Rangarajan, S.1
Walsh, L.2
Lester, W.3
Perry, D.4
Madan, B.5
Laffan, M.6
-
23
-
-
84911383748
-
Long-term safety and efficacy of factor IX gene therapy in hemophilia B
-
pmid:25409372
-
Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371: 1994–2004. doi: 10.1056/NEJMoa1407309 pmid: 25409372
-
(2014)
N Engl J Med
, vol.371
, pp. 1994-2004
-
-
Nathwani, A.C.1
Reiss, U.M.2
Tuddenham, E.G.D.3
Rosales, C.4
Chowdary, P.5
McIntosh, J.6
-
24
-
-
84861139370
-
Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency
-
pmid:22593174
-
Hwu W-L, Muramatsu S -i, Tseng S-H, Tzen K-Y, Lee N-C, Chien Y-H, et al. Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency. Sci Transl Med. 2012;4: 134ra61–134ra61. doi: 10.1126/scitranslmed.3003640 pmid: 22593174
-
(2012)
Sci Transl Med
, vol.4
, pp. 134ra61
-
-
Hwu, W.-L.1
Muramatsu, S.I.2
Tseng, S.-H.3
Tzen, K.-Y.4
Lee, N.-C.5
Chien, Y.-H.6
-
25
-
-
84929378811
-
Improvement and decline in vision with gene therapy in childhood blindness
-
pmid:25936984
-
Jacobson SG, Cideciyan A V, Roman AJ, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372: 1920–6. doi: 10.1056/NEJMoa1412965 pmid: 25936984
-
(2015)
N Engl J Med
, vol.372
, pp. 1920-1926
-
-
Jacobson, S.G.1
Cideciyan, A.V.2
Roman, A.J.3
Sumaroka, A.4
Schwartz, S.B.5
Heon, E.6
-
26
-
-
68349150945
-
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys
-
pmid:19448633
-
Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. Nature Publishing Group; 2009;15: 901–906. doi: 10.1038/nm.1967 pmid: 19448633
-
(2009)
Nat Med. Nature Publishing Group
, vol.15
, pp. 901-906
-
-
Johnson, P.R.1
Schnepp, B.C.2
Zhang, J.3
Connell, M.J.4
Greene, S.M.5
Yuste, E.6
-
27
-
-
84924375707
-
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
-
pmid:25707797
-
Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. Nature Publishing Group; 2015;519: 87–91. doi: 10.1038/nature14264 pmid: 25707797
-
(2015)
Nature. Nature Publishing Group
, vol.519
, pp. 87-91
-
-
Gardner, M.R.1
Kattenhorn, L.M.2
Kondur, H.R.3
von Schaewen, M.4
Dorfman, T.5
Chiang, J.J.6
-
28
-
-
84940767753
-
AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity
-
pmid:26248318
-
Fuchs SP, Martinez-Navio JM, Piatak M, Lifson JD, Gao G, Desrosiers RC, AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLOS Pathog. 2015;11: e1005090. doi: 10.1371/journal.ppat.1005090 pmid: 26248318
-
(2015)
PLOS Pathog
, vol.11
, pp. e1005090
-
-
Fuchs, S.P.1
Martinez-Navio, J.M.2
Piatak, M.3
Lifson, J.D.4
Gao, G.5
Desrosiers, R.C.6
-
29
-
-
84937421013
-
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection
-
pmid:26041300
-
Saunders KO, Wang L, Joyce MG, Yang Z, Balazs AB, Cheng C, et al. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol. 2015;89: 8334–8345. doi: 10.1128/JVI.00908-15 pmid: 26041300
-
(2015)
J Virol
, vol.89
, pp. 8334-8345
-
-
Saunders, K.O.1
Wang, L.2
Joyce, M.G.3
Yang, Z.4
Balazs, A.B.5
Cheng, C.6
-
30
-
-
84911476722
-
Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression
-
pmid:25393537
-
Greig J a, Peng H, Ohlstein J, Medina-Jaszek CA, Ahonkhai O, Mentzinger A, et al. Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression. PLoS One. 2014;9: e112268. doi: 10.1371/journal.pone.0112268 pmid: 25393537
-
(2014)
PLoS One
, vol.9
, pp. e112268
-
-
Greig, J.A.1
Peng, H.2
Ohlstein, J.3
Medina-Jaszek, C.A.4
Ahonkhai, O.5
Mentzinger, A.6
-
31
-
-
84929613728
-
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
-
pmid:25787288
-
Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang Z-Y, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol. 2015;89: 5895–903. doi: 10.1128/JVI.00210-15 pmid: 25787288
-
(2015)
J Virol
, vol.89
, pp. 5895-5903
-
-
Saunders, K.O.1
Pegu, A.2
Georgiev, I.S.3
Zeng, M.4
Joyce, M.G.5
Yang, Z.-Y.6
-
32
-
-
84855584286
-
The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies
-
pmid:21902451
-
Van Rompay KKA, The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses. United States; 2012;28: 16–35. doi: 10.1089/aid.2011.0234 pmid: 21902451
-
(2012)
AIDS Res Hum Retroviruses. United States
, vol.28
, pp. 16-35
-
-
Van Rompay, K.K.A.1
-
33
-
-
84880332648
-
Using Nonhuman Primates to Model HIV Transmission
-
pmid:23666391
-
Fennessey CM, Keele BF, Using Nonhuman Primates to Model HIV Transmission. Curr Opin HIV AIDS. 2013;8: 280–287. pmid: 23666391
-
(2013)
Curr Opin HIV AIDS
, vol.8
, pp. 280-287
-
-
Fennessey, C.M.1
Keele, B.F.2
-
34
-
-
55849127747
-
Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development
-
pmid:18980543
-
Baroncelli S, Negri DRM, Michelini Z, Cara A, Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines. England; 2008;7: 1419–1434. doi: 10.1586/14760584.7.9.1419 pmid: 18980543
-
(2008)
Expert Rev Vaccines. England
, vol.7
, pp. 1419-1434
-
-
Baroncelli, S.1
Negri, D.R.M.2
Michelini, Z.3
Cara, A.4
-
35
-
-
84900820250
-
Simian-Human Immunodeficiency Viruses and Their Impact on Non-Human Primate Models for AIDS
-
Pereira L, Srinivasan P, Smith J, Simian-Human Immunodeficiency Viruses and Their Impact on Non-Human Primate Models for AIDS. Immunodeficiency. 2012; doi: 10.5772/53556
-
(2012)
Immunodeficiency
-
-
Pereira, L.1
Srinivasan, P.2
Smith, J.3
-
36
-
-
84907983318
-
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
-
pmid:25119033
-
Ko S-Y, Pegu A, Rudicell RS, Yang Z, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. Nature Publishing Group; 2014;514: 642–5. doi: 10.1038/nature13612 pmid: 25119033
-
(2014)
Nature. Nature Publishing Group
, vol.514
, pp. 642-645
-
-
Ko, S.-Y.1
Pegu, A.2
Rudicell, R.S.3
Yang, Z.4
Joyce, M.G.5
Chen, X.6
-
37
-
-
85041696060
-
-
pmid:29364886
-
Gaudinski MR, Coates EE, Houser K V, Chen GL, Yamshchikov G, Saunders JG, et al. Safety and pharmacokinetics of the Fc- modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. 2018; 1–20. doi: 10.1371/journal.pmed.1002493 pmid: 29364886
-
(2018)
Safety and pharmacokinetics of the Fc- modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
, pp. 1-20
-
-
Gaudinski, M.R.1
Coates, E.E.2
Houser, K.V.3
Chen, G.L.4
Yamshchikov, G.5
Saunders, J.G.6
-
38
-
-
85042940751
-
Intramuscular Adeno-Associated Virus–Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice
-
van Lieshout LP, Soule G, Sorensen D, Frost KL, He S, Tierney K, et al. Intramuscular Adeno-Associated Virus–Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice. J Infect Dis. 2018; 1–10
-
(2018)
J Infect Dis
, pp. 1-10
-
-
van Lieshout, L.P.1
Soule, G.2
Sorensen, D.3
Frost, K.L.4
He, S.5
Tierney, K.6
-
39
-
-
84929613728
-
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
-
pmid:25787288
-
Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang Z-Y, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol. 2015;89: 5895–5903. doi: 10.1128/JVI.00210-15 pmid: 25787288
-
(2015)
J Virol
, vol.89
, pp. 5895-5903
-
-
Saunders, K.O.1
Pegu, A.2
Georgiev, I.S.3
Zeng, M.4
Joyce, M.G.5
Yang, Z.-Y.6
-
40
-
-
0013442744
-
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
-
Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Analgesia. 2003;101: 2963–2972
-
(2003)
Analgesia
, vol.101
, pp. 2963-2972
-
-
Manno, C.S.1
Chew, A.J.2
Hutchison, S.3
Larson, P.J.4
Herzog, R.W.5
Arruda, V.R.6
-
41
-
-
77951916324
-
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody
-
pmid:20377413
-
Jacobson JM, Thompson M a, Lalezari JP, Saag MS, Zingman BS, D’Ambrosio P, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010;201: 1481–7. doi: 10.1086/652190 pmid: 20377413
-
(2010)
J Infect Dis
, vol.201
, pp. 1481-1487
-
-
Jacobson, J.M.1
Thompson, M.A.2
Lalezari, J.P.3
Saag, M.S.4
Zingman, B.S.5
D’Ambrosio, P.6
-
42
-
-
0141514408
-
DNA vaccine strategies: Candidates for immune modulation and immunization regimens
-
pmid:14511953
-
Doria-Rose NA, Haigwood NL, DNA vaccine strategies: Candidates for immune modulation and immunization regimens. Methods. 2003;31: 207–216. doi: 10.1016/S1046-2023(03)00135-X pmid: 14511953
-
(2003)
Methods
, vol.31
, pp. 207-216
-
-
Doria-Rose, N.A.1
Haigwood, N.L.2
-
43
-
-
57549090220
-
Intramuscular administration of AAV1-lipoprotein lipaseS447X lowers triglycerides in lipoprotein lipase-deficient patients
-
pmid:18802015
-
Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, et al. Intramuscular administration of AAV1-lipoprotein lipaseS447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28: 2303–2304. doi: 10.1161/ATVBAHA.108.175620 pmid: 18802015
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, pp. 2303-2304
-
-
Stroes, E.S.1
Nierman, M.C.2
Meulenberg, J.J.3
Franssen, R.4
Twisk, J.5
Henny, C.P.6
-
44
-
-
84878746264
-
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
-
pmid:23442094
-
Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T, Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy. Hum Gene Ther Methods. 2013;24: 59–67. doi: 10.1089/hgtb.2012.243 pmid: 23442094
-
(2013)
Hum Gene Ther Methods
, vol.24
, pp. 59-67
-
-
Louis Jeune, V.1
Joergensen, J.A.2
Hajjar, R.J.3
Weber, T.4
-
45
-
-
84877930020
-
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells
-
pmid:23325831
-
Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood. 2013;121: 2224–2233. doi: 10.1182/blood-2012-10-460733 pmid: 23325831
-
(2013)
Blood
, vol.121
, pp. 2224-2233
-
-
Martino, A.T.1
Basner-Tschakarjan, E.2
Markusic, D.M.3
Finn, J.D.4
Hinderer, C.5
Zhou, S.6
-
46
-
-
85031746439
-
Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity
-
pmid:29055620
-
Paulk NK, Pekrun K, Zhu E, Nygaard S, Li B, Xu J, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol Ther. Elsevier Ltd.; 2018;26: 289–303. doi: 10.1016/j.ymthe.2017.09.021 pmid: 29055620
-
(2018)
Mol Ther. Elsevier Ltd.
, vol.26
, pp. 289-303
-
-
Paulk, N.K.1
Pekrun, K.2
Zhu, E.3
Nygaard, S.4
Li, B.5
Xu, J.6
-
47
-
-
84947022242
-
In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector
-
pmid:26235624
-
Zinn E, Pacouret S, Khaychuk V, Turunen HT, Carvalho LS, Andres-Mateos E, et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. The Authors; 2015;12: 1056–1068. doi: 10.1016/j.celrep.2015.07.019 pmid: 26235624
-
(2015)
Cell Rep. The Authors
, vol.12
, pp. 1056-1068
-
-
Zinn, E.1
Pacouret, S.2
Khaychuk, V.3
Turunen, H.T.4
Carvalho, L.S.5
Andres-Mateos, E.6
-
48
-
-
85016568747
-
The Immunoregulatory Roles of Antibody Glycosylation
-
pmid:28385520
-
Jennewein MF, Alter G, The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. Elsevier Ltd; 2017;38: 358–372. doi: 10.1016/j.it.2017.02.004 pmid: 28385520
-
(2017)
Trends Immunol. Elsevier Ltd
, vol.38
, pp. 358-372
-
-
Jennewein, M.F.1
Alter, G.2
-
49
-
-
84962467040
-
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination
-
pmid:26982805
-
Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, et al. Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. PLoS Pathog. 2016;12: 1–18. doi: 10.1371/journal.ppat.1005456 pmid: 26982805
-
(2016)
PLoS Pathog
, vol.12
, pp. 1-18
-
-
Mahan, A.E.1
Jennewein, M.F.2
Suscovich, T.3
Dionne, K.4
Tedesco, J.5
Chung, A.W.6
-
50
-
-
85016419499
-
Modulating IgG effector function by Fc glycan engineering
-
pmid:28289219
-
Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang L-X, Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci. 2017;114: 3485–3490. doi: 10.1073/pnas.1702173114 pmid: 28289219
-
(2017)
Proc Natl Acad Sci
, vol.114
, pp. 3485-3490
-
-
Li, T.1
DiLillo, D.J.2
Bournazos, S.3
Giddens, J.P.4
Ravetch, J.V.5
Wang, L.-X.6
-
51
-
-
85039066883
-
Beyond binding: Antibody effector functions in infectious diseases
-
pmid:29063907
-
Lu LL, Suscovich TJ, Fortune SM, Alter G, Beyond binding: Antibody effector functions in infectious diseases. Nat Rev Immunol. Nature Publishing Group; 2018;18: 46–61. doi: 10.1038/nri.2017.106 pmid: 29063907
-
(2018)
Nat Rev Immunol. Nature Publishing Group
, vol.18
, pp. 46-61
-
-
Lu, L.L.1
Suscovich, T.J.2
Fortune, S.M.3
Alter, G.4
-
52
-
-
34249796660
-
The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain
-
pmid:17513762
-
Miranda LR, Duval M, Doherty H, Seaman MS, Posner MR, Cavacini L a, The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J Immunol. 2007;178: 7132–8. pmid: 17513762
-
(2007)
J Immunol
, vol.178
, pp. 7132-7138
-
-
Miranda, L.R.1
Duval, M.2
Doherty, H.3
Seaman, M.S.4
Posner, M.R.5
Cavacini, L.A.6
-
53
-
-
84992735645
-
Modulating Antibody Functionality in Infectious Disease and Vaccination
-
pmid:27756530
-
Gunn BM, Alter G, Modulating Antibody Functionality in Infectious Disease and Vaccination. Trends Mol Med. Elsevier Ltd; 2016;22: 969–982. doi: 10.1016/j.molmed.2016.09.002 pmid: 27756530
-
(2016)
Trends Mol Med. Elsevier Ltd
, vol.22
, pp. 969-982
-
-
Gunn, B.M.1
Alter, G.2
-
54
-
-
84896120124
-
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission
-
pmid:24509526
-
Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. Nature Publishing Group; 2014;20: 296–300. doi: 10.1038/nm.3471 pmid: 24509526
-
(2014)
Nat Med. Nature Publishing Group
, vol.20
, pp. 296-300
-
-
Balazs, A.B.1
Ouyang, Y.2
Hong, C.M.3
Chen, J.4
Nguyen, S.M.5
Rao, D.S.6
-
55
-
-
84880296945
-
Broad protection against influenza infection by vectored immunoprophylaxis in mice
-
pmid:23728362
-
Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D, Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol. Nature Publishing Group; 2013;31: 647–52. doi: 10.1038/nbt.2618 pmid: 23728362
-
(2013)
Nat Biotechnol. Nature Publishing Group
, vol.31
, pp. 647-652
-
-
Balazs, A.B.1
Bloom, J.D.2
Hong, C.M.3
Rao, D.S.4
Baltimore, D.5
-
56
-
-
85032818556
-
Recent Insights into the HIV/AIDS Pandemic
-
pmid:28357381
-
Becerra JC, Bildstein LS, Gach JS, Recent Insights into the HIV/AIDS Pandemic. Microb Cell. 2016;3: 450–474. pmid: 28357381
-
(2016)
Microb Cell
, vol.3
, pp. 450-474
-
-
Becerra, J.C.1
Bildstein, L.S.2
Gach, J.S.3
-
57
-
-
85010902371
-
Use of broadly neutralizing antibodies for HIV-1 prevention
-
pmid:28133803
-
Pegu A, Hessell AJ, Mascola JR, Haigwood NL, Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev. 2017;275: 296–312. doi: 10.1111/imr.12511 pmid: 28133803
-
(2017)
Immunol Rev
, vol.275
, pp. 296-312
-
-
Pegu, A.1
Hessell, A.J.2
Mascola, J.R.3
Haigwood, N.L.4
-
58
-
-
84879302728
-
HIV-1 neutralizing antibodies: understanding nature ‘ s pathways
-
pmid:23772623
-
Mascola JR, Haynes BF, HIV-1 neutralizing antibodies: understanding nature ‘ s pathways. Immunol Rev. 2013;254: 225–244. doi: 10.1111/imr.12075 pmid: 23772623
-
(2013)
Immunol Rev
, vol.254
, pp. 225-244
-
-
Mascola, J.R.1
Haynes, B.F.2
-
59
-
-
84964896857
-
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
-
pmid:27064278
-
Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, et al. Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog. 2016;12. doi: 10.1371/journal.ppat.1005537 pmid: 27064278
-
(2016)
PLoS Pathog
, vol.12
-
-
Mason, R.D.1
Welles, H.C.2
Adams, C.3
Chakrabarti, B.K.4
Gorman, J.5
Zhou, T.6
-
60
-
-
84866495323
-
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
-
pmid:22999947
-
Kwong PD, Mascola JR, Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. Immunity. Elsevier Inc.; 2012;37: 412–425. doi: 10.1016/j.immuni.2012.08.012 pmid: 22999947
-
(2012)
Immunity. Elsevier Inc
, vol.37
, pp. 412-425
-
-
Kwong, P.D.1
Mascola, J.R.2
-
62
-
-
84865737411
-
Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections
-
pmid:22807524
-
Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, et al. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis. 2012;206: 915–23. doi: 10.1093/infdis/jis462 pmid: 22807524
-
(2012)
J Infect Dis
, vol.206
, pp. 915-923
-
-
Adhikari, R.P.1
Ajao, A.O.2
Aman, M.J.3
Karauzum, H.4
Sarwar, J.5
Lydecker, A.D.6
-
63
-
-
84955741596
-
Generating Monoclonal Antibodies
-
Greenfield EA, Generating Monoclonal Antibodies. A Labratory Man. 2014; 201–221
-
(2014)
A Labratory Man
, pp. 201-221
-
-
Greenfield, E.A.1
-
64
-
-
84904497424
-
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4
-
Pegu A, Yang Z, Boyington JC, Wu L, Ko S, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4receptor. 2014;6
-
(2014)
receptor
, vol.6
-
-
Pegu, A.1
Yang, Z.2
Boyington, J.C.3
Wu, L.4
Ko, S.5
Schmidt, S.D.6
-
65
-
-
45849125030
-
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays
-
pmid:18432938
-
Montefiori DC, Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005;Chapter 12: Unit 12.11. doi: 10.1002/0471142735.im1211s64 pmid: 18432938
-
(2005)
Curr Protoc Immunol
, vol.Chapter 12
, pp. Unit 12.11
-
-
Montefiori, D.C.1
-
66
-
-
84940737670
-
Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models
-
pmid:26285041
-
Roederer M, Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models. PLoS Pathog. 2015; 1–14. doi: 10.1371/journal.ppat.1005100 pmid: 26285041
-
(2015)
PLoS Pathog
, pp. 1-14
-
-
Roederer, M.1
-
67
-
-
84974718820
-
Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
-
pmid:27247400
-
Li H, Wang S, Kong R, Ding W, Lee F-H, Parker Z, et al. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci. 2016;113: E3413–E3422. doi: 10.1073/pnas.1606636113 pmid: 27247400
-
(2016)
Proc Natl Acad Sci
, vol.113
, pp. E3413-E3422
-
-
Li, H.1
Wang, S.2
Kong, R.3
Ding, W.4
Lee, F.-H.5
Parker, Z.6
|